| 26.81 0.71 (2.72%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.41 | 1-year : | 35.49 |
| Resists | First : | 28.61 | Second : | 30.38 |
| Pivot price | 27.33  |
|||
| Supports | First : | 25.73 | Second : | 21.41 |
| MAs | MA(5) : | 26.4 |
MA(20) : | 27.72 |
| MA(100) : | 30.08 |
MA(250) : | 33.3 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 17.2 |
D(3) : | 14.6 |
| RSI | RSI(14): 39.9 |
|||
| 52-week | High : | 48.59 | Low : | 25.73 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PCRX ] has closed above bottom band by 36.2%. Bollinger Bands are 2.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.1 - 27.29 | 27.29 - 27.44 |
| Low: | 25.84 - 26.04 | 26.04 - 26.19 |
| Close: | 26.55 - 26.86 | 26.86 - 27.1 |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Tue, 23 Apr 2024
Pacira BioSciences (NASDAQ:PCRX) Hits New 1-Year Low at $25.74 - MarketBeat
Sun, 21 Apr 2024
Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Popularity With Investors Is Clear - Yahoo Movies UK
Fri, 19 Apr 2024
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $49.50 Average Price Target from Analysts - MarketBeat
Thu, 11 Apr 2024
Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns ... - Yahoo Finance
Thu, 11 Apr 2024
Pacira BioSciences (NASDAQ:PCRX) sheds US$55m, company earnings and investor returns have been trending ... - Simply Wall St
Tue, 09 Apr 2024
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts - Markets Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 47 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 108.2 (%) |
| Shares Short | 3,740 (K) |
| Shares Short P.Month | 4,170 (K) |
| EPS | 0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.71 |
| Profit Margin | 6.2 % |
| Operating Margin | 18.7 % |
| Return on Assets (ttm) | 3.3 % |
| Return on Equity (ttm) | 5 % |
| Qtrly Rev. Growth | 5.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 14.51 |
| EBITDA (p.s.) | 3.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 155 (M) |
| Levered Free Cash Flow | 107 (M) |
| PE Ratio | 30.12 |
| PEG Ratio | 0.8 |
| Price to Book value | 1.43 |
| Price to Sales | 1.84 |
| Price to Cash Flow | 8.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|